The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.

The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.

Cookies

This site uses cookies for site interaction analysis with a purpose of service quality enhancing and uninterrupted site work. More details in Cookies Policy
Accept
10 April 2020

Additional Batches of Imustat Already Hit the Shelves

10 April 2020

Darnitsa Pharmaceutical Company sent 100 thousand packs of Imustat to pharmacies. The Company promptly ensured the production of the antiviral drug in response to multiple requests from consumers and pharmacy chains.

Imustat is an antiviral medicine, which is available in tablets. It is recommended for adults to reduce the duration and severity of the disease and to alleviate its main symptoms. The use of the drug reduces the incidence of complications associated with the flu. Imustat is low-toxic and does not have a negative impact on the human body.

Dmytro Shymkiv, Chairman of the Board of Directors of Darnitsa Group:

“Despite the turbulence of the situation, we keep our promises and provide Ukrainians with antiviral medicines. Imustat has already begun to arrive to pharmacies. We have the necessary raw materials and supplies to ensure the production of new batches, if necessary.”

As previously reported, on March 26, Darnitsa commenced the production of additional batches of the antiviral drug “Imustat” in order to satisfy the increasing demand.

Share:
Specialized edition for medical institutions and doctors.